Skip to main content

9 Result(s)

within Bengt Hamrén Remove this filter

and

  1. No Access

    Article

    Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis

    Cotadutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor agonist peptide. The objective of this analysis was to develop a population pharmacokinetic (popPK) model of cotadutide, and to ...

    Hongtao Yu, Magnus Åstrand, Jenny Cheng, Kaila Nitin… in Clinical Pharmacokinetics (2024)

  2. No Access

    Article

    Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease

    Roxadustat is a novel, small-molecule, first-in-class therapeutic that stimulates erythropoiesis by inhibiting hypoxia-inducible factor prolyl hydroxylase enzymes. This agent (roxadustat) is in clinical develo...

    Dinko Rekić, Virginie Kerbusch-Herben, Mats Någård, James Chou… in Clinical Pharmacokinetics (2021)

  3. Article

    Open Access

    Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response

    In this paper we investigated a new method for dose-response analysis of longitudinal data in terms of precision and accuracy using simulations.

    Gustaf J. Wellhagen, Bengt Hamrén, Maria C. Kjellsson… in Pharmaceutical Research (2020)

    Download PDF (2154 KB) View Article

  4. No Access

    Article

    Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease

    Ticagrelor, a reversible P2Y12 platelet inhibitor, is under investigation as a sickle cell disease (SCD) therapy in children. HESTIA1 (NCT02214121) was the first ticagrelor study generating pharmacokinetic (PK), ...

    Carl Amilon, Mohammad Niazi, Anders Berggren, Magnus Åstrand… in Clinical Pharmacokinetics (2019)

  5. No Access

    Article

    Impact of a five-dimensional framework on R&D productivity at AstraZeneca

    In 2011, AstraZeneca set out to improve its research and development (R&D) productivity by focusing decision-making using a framework with five technical determinants: the right target, right tissue, right saf...

    Paul Morgan, Dean G. Brown, Simon Lennard… in Nature Reviews Drug Discovery (2018)

  6. Article

    Open Access

    Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection

    Population model-based (pharmacometric) approaches are widely used for the analyses of phase IIb clinical trial data to increase the accuracy of the dose selection for phase III clinical trials. On the other h...

    Yasunori Aoki, Daniel Röshammar… in Journal of Pharmacokinetics and Pharmacody… (2017)

    Download PDF (6247 KB) View Article

  7. No Access

    Article

    Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia

    Data from two clinical studies (hyperCholesterolaemia in cHildren and Adolescents taking Rosuvastatin OpeN label [CHARON; NCT01078675] and Study 4522IL/0086) were used to describe rosuvastatin pharmacokinetics...

    Merran Macpherson, Bengt Hamrén… in European Journal of Clinical Pharmacology (2016)

  8. No Access

    Article

    Population Pharmacokinetics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor **melagatran, in Atrial Fibrillation Patients Receiving Long-Term Anticoagulation Therapy

    **melagatran is an oral direct thrombin inhibitor for the prevention of thromboembolic disease. After oral administration, ximelagatran is rapidly absorbed and bioconverted to its active form, melagatran.

    Sofie Bååthe, Bengt Hamrén, Mats O. Karlsson, Maria Wollbratt… in Clinical Pharmacokinetics (2006)

  9. No Access

    Article

    Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral **melagatran

    Objective: **melagatran, an oral direct thrombin inhibitor, is rapidly bioconverted to melagatran, its active form. The objective of this population analysis was to characterise the pharmacokinet...

    Dr Ulf G. Eriksson, Jaap W. Mandema, Mats O. Karlsson… in Clinical Pharmacokinetics (2003)